Indication
Early breast cancer hormone receptor positive and postmenopausal
Early breast cancer that is hormone receptor–positive in postmenopausal individuals refers to invasive mammary carcinoma confined to the breast and regional lymph nodes (typically stages I through IIIA) in women who have undergone the permanent cessation of ovarian function. Read more about Early breast cancer hormone receptor positive and postmenopausal
49 drugs 34 manufacturers
Drugs that treat it
Common Early breast cancer hormone receptor positive and postmenopausal therapies.
ANASTROZOLE
LETROZOLE
ANASTROZOLE
ANASTROZOLE
LETROZOLE
ANASTROZOLE
LETROZOLE
ANASTROZOLE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonEarly breast cancer that is hormone receptor–positive in postmenopausal individuals refers to invasive mammary carcinoma confined to the breast and regional lymph nodes (typically stages I through IIIA) in women who have undergone the permanent cessation of ovarian function.
The condition affects the breast parenchyma and regional lymphatic system, with tumor growth predominantly driven by the binding of circulating estrogen or progesterone to cellular receptors.
Pathophysiologically, the tumor cells express estrogen receptors, progesterone receptors, or both, making them dependent on hormonal signaling pathways for cellular proliferation and survival.
In this postmenopausal demographic, the primary source of endogenous estrogen shifts from the ovaries to the peripheral aromatization of adrenal androgens in tissues such as adipose and liver, defining a key physiological vulnerability targeted in clinical management.
- nih.gov
Early breast cancer that is hormone receptor–positive in postmenopausal individuals refers to invasive mammary carcinoma confined to the breast and regional lymph nodes (typically stages I through IIIA) in women who have undergone the permanent cessation of ovarian function In this postmenopausal demographic, the primary source of endogenous estrogen shifts from the ovaries to the peripheral aromatization of adrenal androgens in tissues such as adipose and liver, defining a key physiological vul...
- nih.gov
Early breast cancer that is hormone receptor–positive in postmenopausal individuals refers to invasive mammary carcinoma confined to the breast and regional lymph nodes (typically stages I through IIIA) in women who have undergone the permanent cessation of ovarian function
- cancer.gov
The condition affects the breast parenchyma and regional lymphatic system, with tumor growth predominantly driven by the binding of circulating estrogen or progesterone to cellular receptors Pathophysiologically, the tumor cells express estrogen receptors, progesterone receptors, or both, making them dependent on hormonal signaling pathways for cellular proliferation and survival In this postmenopausal demographic, the primary source of endogenous estrogen shifts from the ovaries to the peripher...
- komen.org
The condition affects the breast parenchyma and regional lymphatic system, with tumor growth predominantly driven by the binding of circulating estrogen or progesterone to cellular receptors Pathophysiologically, the tumor cells express estrogen receptors, progesterone receptors, or both, making them dependent on hormonal signaling pathways for cellular proliferation and survival
Personalize your experience
Follow Early breast cancer hormone receptor positive and postmenopausal and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.